IoM Report On Postmarketing Study Ethics Could Drive Broad Overhaul Of Informed Consent
Executive Summary
An Institute of Medicine report on ethical and scientific issues in drug safety studies could lead to a broad restructuring of informed consent documents in postmarketing clinical trials
You may also be interested in...
FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan
The Institute of Medicine urges the agency to create a publicly available document setting forth benefits and risks of drugs, with periodic updates, but FDA says it has no extra resources to handle such an effort.
Brilinta Advisory Cmte. Nod Creates Postmarketing Study Quandary For FDA
With the Cardiovascular and Renal Drugs Advisory Committee's endorsement of AstraZeneca's antiplatelet agent Brilinta (ticagrelor) behind it, FDA now faces a potential challenge in devising a postmarketing study commitment aimed at addressing efficacy questions in U.S. acute coronary syndrome patients that does not also run into ethical roadblocks
Brilinta Advisory Cmte. Nod Creates Postmarketing Study Quandary For FDA
With the Cardiovascular and Renal Drugs Advisory Committee's endorsement of AstraZeneca's antiplatelet agent Brilinta (ticagrelor) behind it, FDA now faces a potential challenge in devising a postmarketing study commitment aimed at addressing efficacy questions in U.S. acute coronary syndrome patients that does not also run into ethical roadblocks